Stock BRM BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Bristol-Myers Squibb Company Deutsche Boerse AG

Equities

BRM

US1101221083

Real-time Estimate Tradegate
Other stock markets
 03:37:17 2024-07-12 pm EDT 		5-day change 1st Jan Change
37.3 EUR -1.55% Intraday chart for Bristol-Myers Squibb Company +2.09% -19.95%
03:37pm UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating MT
Jul. 11 Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Ex-dividend day
FA
Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says
MT
Eisai Co., Ltd. Agrees to End Its Global Strategic Collaboration with Bristol Myers Squibb for the Co-Development and Co-Commercialization of farletuzumab ecteribulin
CI
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise
MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours
MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment
MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees
MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees
MT
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer
CI
US FDA approves Bristol Myers' colorectal cancer therapy
RE
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo
CI
PTC Therapeutics, Inc. and Hopewell Campus Owner, LLC, as Successor-In-Interest to Bristol-Myers Squibb Company Enter into an Amendment and Restatement of the Lease of Office, Production and Laboratory Space At A Facility Located in Hopewell Township, New Jersey
CI
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment
MT
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5
MT
Bristol Myers: Board declares dividend
CF
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024
CI
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors
MT
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
CI
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb
MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BRM Stock
  5. News Bristol-Myers Squibb Company
  6. Highlights